Opinion|Videos|November 17, 2026

Preparing for Systemic Treatment Options: Meeting the Moment in Vitiligo

Patients rank stabilization above repigmentation, and the timeline for meaningful improvement can stretch to three years. Dr. Hamzavi lays out the goals and realistic expectations that should guide systemic therapy.

This episode, "Preparing for Systemic Treatment Options: Meeting the Moment in Vitiligo," asks what patients actually want from treatment, and how long it realistically takes to get there.

Dr. Hamzavi credits Dr. Desai's advocacy work for helping bring society and the scientific community together to support new vitiligo therapies, building on foundational research from the mid-2010s that asked patients what mattered most. That research found stabilization, simply stopping the disease from getting worse, ranked as the top priority, ahead of repigmentation itself. Patients reported feeling satisfied with twenty-five to fifty percent repigmentation by six months, though their ultimate goal was closer to seventy-five percent repigmentation on the face and around fifty percent on the torso, reflecting how differently patients weigh visible versus less-visible areas of the body.

Dr. Hamzavi lists four goals he applies clinically: stabilize the disease first, repigment as quickly as reasonably possible, maintain any pigment gained, and ensure the resulting color is a good match so contrast with surrounding skin is minimized. When Dr. Taylor asks him to restate the expected timeline for the audience, he clarifies that visible repigmentation typically takes six months to a year at minimum, and reaching seventy-five percent facial repigmentation with fifty percent on the body can take closer to three years. He is careful to note that slower responders should not be abandoned simply because others progress faster.

He closes by emphasizing that outcomes depend on more than pharmacology. Sustaining pigment once achieved matters deeply to patients, since losing hard-won repigmentation is emotionally devastating, and he describes vitiligo as a condition that can bruise the soul independent of its physical extent. Combining clinical science with genuine engagement, he argues, produces more fulfilled patients overall, even among those who never reach full repigmentation, because the relationship itself supports their psychosocial wellbeing alongside physical treatment.

The next episode in this series, "Choosing Among Emerging Systemic Agents for Vitiligo," looks at how the panel will choose among emerging oral agents and manage their risks.

This video was supported independently by Pfizer.


Related to this article